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RUMUSAN TRANSDERMAL TOPIKAL GEL SILDENAFIL YANG BARU 
GEL SILDENAFIL TOPIKAL BARU UNTUK PENINGKATAN 
KEBOLEHHIDUPAN FLAP KULIT DALAM MODEL ARNAB 
ABSTRAK 
Kebolehhidupan flap kulit merupakan salah satu hasil yang paling 
diutamakan dalam pembedahan rekonstruktif. Pelbagai aplikasi agen farmakologi 
dengan rejimen dos yang berbeza telah menunjukkan kebolehan meningkatkan 
kebolehhidupan flap dengan darjah peningkatan yang berbeza-beza. Kajian ini 
bertujuan untuk menghasilkan satu perumusan gel topikal sildenafil sitrat yang 
berkesan dalam menambahbaik kebolehhidupan flap kulit. Pencirian ciri-ciri 
fizikokimia dan ujian kestabilan asas telah dijalankan pada perumusan gel tersebut. 
Pembedahan flap kulit (14 cm x 5 cm) berdasarkan arteri epigastrik atas kaudal telah 
dijalankan pada sembilan ekor arnab New Zealand White (julat berat antara 2.5-3.2 
kg). Satu aliquot 1 ml gel yang mengandungi sildenafil sitrat (3 mg) disapukan 
serta-merta selepas pembedahan pada separuh hujung bahagian flap dalam 
kumpulan rawatan (n = 3), manakala 1 ml gel tanpa sildenafil dijadikan kumpulan 
kawalan kenderaan (n = 3), dan tiada sebarang ubatan digunakan untuk kumpulan 
kawalan (n = 3). Perfusi darah pada bahagian hujung flap dan indeks nekrotik flap 
kulit diukur secara berterusan selama 10 hari selepas pembedahan flap dengan 
xxvi 
 
menggunakan meter pengaliran darah berasaskan Doppler laser (LDF) dan 
planimetri satah berdua. Kumpulan rawatan telah menunjukkan pengurangan 
signifikan pada indeks nekrotik (min ± sisihan piawai) berbanding dengan 
kumpulan kawalan dan kawalan kenderaan (kumpulan rawatan, 0.25 ± 0.43% vs. 
kawalan kenderaan 5.41 ± 3.50% vs. kawalan 5.41 ± 1.53%; p = 0.017). 
Peningkatan awal yang signifikan pada perfusi darah di bahagian hujung flap 
berlaku dalam 24 jam pertama selepas pembedahan (p < 0.001). Keputusan uji kaji 
ex vivo kadar penelapan dadah sildenafil merentasi kulit arnab (n = 3) menunjukkan 
bahawa kadar penelapan kandungan dadah melebihi separuh berlaku selepas enam 
jam (58.03%) dan penelapan dadah sebanyak 95.84% berlaku dalam tempoh 24 jam 
pertama. Pelepasan dadah perumusan gel sildenafil didapati menepati kinetik tertib 
pertama untuk tempoh 24 jam pertama dan pemalar eksponen pelepasan, n, didapati 
melebihi 1.0 dengan analisa persamaan Korsmeyer-Peppas. Hasil kedua-dua analisis 
kinetik ini menunjukkan bahawa perumusan gel sildenafil tersebut mempunyai ciri-
ciri pelepasan dadah yang terkawal dengan pelepasan dadah berpanjangan. Secara 
kesimpulannya, kajian yang menggunakan model arnab ini memperlihatkan bahawa 
aplikasi tunggal perumusan gel sildenafil (3 mg/ml) berupaya meningkatkan perfusi 
darah peredaran mikro pada bahagian hunjung flap dan menambahbaik 
kebolehhidupan flap kulit. 
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A NEW TOPICAL TRANSDERMAL SILDENAFIL GEL FORMULATION 
TO IMPROVE SKIN FLAP VIABILITY IN A RABBIT MODEL  
ABSTRACT 
Skin flap survival is one of the most important outcomes in reconstructive 
surgery. Various applications of pharmacological agents with different dosing 
regimens have been shown to improve flap survival experimentally with varying 
degrees. This study aimed to produce an effective topical gel formulation of 
sildenafil citrate for the improvement of skin flap survival. Characterization of 
physicochemical properties and basic stability tests were carried out on the gel 
formulation. Skin flaps (14 cm x 5 cm) based on superficial inferior epigastric 
vessels was designed and raised on nine New Zealand White rabbits (weight range 
2.5-3.2 kg). An aliquot of 1 ml gel consisted of sildenafil citrate (3 mg) was applied 
immediately post-surgery to the distal half of the flap in treatment group (n = 3) 
while 1 ml gel without sildenafil was applied to vehicle control group (n = 3), and 
none was applied to controls (n = 3). Blood perfusion at the flap distal end and mean 
necrotic index of the skin flaps were measured continually for 10 days after the flap 
surgery using laser Doppler flowmetry (LDF) and 2-plane planimetry, respectively. 
Necrotic index (mean ± standard deviation) in the treatment group was significantly 
lower compared to control and vehicle control group (Treatment group, 0.25 ± 
xxviii 
 
0.43% vs. vehicle control 5.41 ± 3.50% vs. control 5.41 ± 1.53%; p = 0.017). Early 
blood perfusion improvement was observed in the treatment group with significant 
increase seen at flap distal end on the first 24 hours post-surgery (p < 0.001). Ex 
vivo drug release data of the sildenafil gel across rabbit skin (n = 3) showed that 
more than half of the drug content were released after six hours (58.03%) and 
95.84% of the drug were released after 24 hours. The drug release in the first 24 
hours was found to follow the first-order kinetic model, and the release exponent, n, 
was found to be greater than 1.0 using the Korsmeyer-Peppas equation. Both kinetic 
analyses showed that the current sildenafil gel formulation demonstrated controlled 
release properties for extended drug release. In conclusion, this study demonstrated 
that single application of the current gel formulation of sildenafil (3 mg/ml) 
significantly increased microcirculatory blood perfusion at the flap distal end and 
improved skin flap survival in rabbits.  
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CHAPTER 1  
 
INTRODUCTION 
 
1.1 An overview of skin flap surgery 
1.1.1 Definition of flap 
Flap surgery is a common procedure in plastic and reconstructive surgery. It is a 
technique performed to cover up an open wound where the edge of the wound cannot 
be closed primarily. The procedure is particularly useful in the reconstruction of 
bodily defects left behind by traumatic events, or after the removal of tumour 
growths such as cancer excisions from the head and neck region or mastectomy 
(Bagdas et al., 2014; Khouri et al., 1998). 
 
The procedure in flap surgery involves the lifting of any type of tissue from the 
donor site, and moved to the recipient site, usually a wound with significant tissue 
loss. The piece of tissue transferred in this procedure is called a flap. In a broad sense, 
a flap is similar to a graft. However, a flap is a piece of living tissue raised from the 
donor site with its underlying vasculature intact, while a graft is a tissue transplanted 
without intact blood vessels (Gurtner and Neligan, 2017). This allows the flap to 
have a better survival rate compared to a graft as a graft’s survival relies solely upon 
growth of blood vessels after being transplanted to the recipient site (Semer and 
Adler-Lavan, 2001).  
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Depending on the reconstructive requirements, a flap can take the form of many 
shapes with different tissue compositions. It can be as simple as a skin tissue 
advancement, or it can be a composite of different tissue types that includes muscle, 
fat, bone and fascia. Usually, the choice of flap tissue is made according to like for 
like basis, meaning that the donor site with similar tissue structure to the recipient 
site is preferred (Minas, 2017).  
 
1.1.2 History of flap surgery 
As early as 600 B.C., records of upper extremity flap reconstructions have been 
documented by Susruta of India in Samahita. According to the record, nasal 
reconstruction using a regional pedicled flap from the cheek have been described. 
During the Roman era, local tissue rearrangements of the head and neck region have 
been documented by Celsus (25 A.D.) and Oribasius (325 – 403 A.D.) using random 
circulation pedicled flaps. However, further documentation of flap surgery or any 
record of technical advancement is scarce for nearly a millennium, until the 
Renaissance era in Europe (Tschoi et al., 2009). 
 
During the early 15
th
 century, Gustavo Branca of Italy and his son Antonio began 
experimenting and described the use of local forehead flap for the nose, which they 
gained insights from the texts of Susruta (Tenenhaus et al., 2008). It was during this 
time that the first nasal reconstruction using a distant flap harvested from the arm 
was documented (McDowell et al., 1952).  
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With advances in the accuracy of anatomic depictions from the Renaissance era, 
through the Industrial Revolution, leading towards the period of the world wars, 
coupled with vast improvements in surgical techniques became the basis for the 
improvement of flap surgery techniques. Flap surgery enters a phase of significant 
improvement in the period of the two world wars. During that period, it was realised 
that reconstruction of the extremities, particularly the hand was very important for 
maintaining the function of the upper limb. This led to the transfer of flap surgery 
techniques used in head and neck reconstruction onto the reconstruction of upper 
extremities. At the same time, improvements in distant flap reconstruction techniques 
allows for the advent of hand surgery, committed towards addressing major upper 
extremity trauma during World War II (Chambers et al., 2010; Chambers and Ray, 
2009; Fang and Chung, 2014). 
 
With the arrival of microvascular free tissue transfer in the 20
th
 century, flap surgery 
techniques took another leap forward. Before this, flap surgery was mostly localised 
pedicled flaps. The introduction of modified operating microscope by Julius 
Jacobson and Ernesto Suarez in the 1960s made free tissue transfer possible, thus 
bringing forth the era of free flaps which opened up endless possibilities and 
applications of flap tissue transfer in plastic and reconstructive surgery (Fang and 
Chung, 2014). 
 
In the following decades, with the availability of information, surgical literature 
documenting each innovative technique could be widely disseminated, allowing 
continued development of flap surgery up to this date (Lamberty et al., 1990). 
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1.1.3 Classification of skin flap 
Skin flaps are a type of flap tissue that consist of skin and subcutaneous tissue lifted 
from the donor site together with its underlying vasculature. The flap may or may not 
come together with the fascia depending on its intended use. According to literature, 
skin flap comes in a multitude of shapes and forms, causing the classifications and 
naming of skin flap to be varied. The principle of classifying the skin flaps is 
intended to aid in the communication among surgeon, thus similar flaps can have 
different names on different occasions, depending on the purpose of communication. 
Nonetheless, the two most common principles of classifying skin flaps are based on 
the type of blood supply, or according to whether the flap is a pedicled or free flap 
(Hallock, 2004). 
 
Based on the type of blood supply, skin flaps can be categorized into two major types, 
i.e. axial pattern flaps and random flaps. Axial pattern flaps are supplied by a specific, 
identifiable artery running along the longitudinal portion of the flap. The identified 
blood vessel (pedicle) will serve as the main blood supply for the flap, allowing the 
surrounding tissue to be detached from the donor site while maintaining the viability 
of the flap tissue. Axial pattern flaps have high success rates as a result of good 
circulation of blood supply from the pedicle. However, careful planning in locating 
the blood vessels that will be used as the pedicle is crucial and injury towards the 
pedicle will often result in failure of axial pattern flaps (Semer and Adler-Lavan, 
2001). 
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On the other hand, random flaps are supplied through non-specified blood vessels, or 
in a more accurate manner, there is an absence of a main artery running across the 
random flap. Hence, the circulation of the random flap is dependent on the number of 
microvascular connections that the pedicle has. The more profuse the vascular 
connection, the greater the chance of survival of the random flap. Although the blood 
supply in a random flap may not be as reliable in an axially supplied flap, random 
flaps have its advantages in ease of application, allowing it to be created and used on 
almost any part of the human body (McGregor and Morgan, 1973).  
 
Apart from classifying skin flaps according to the type of blood supply, it can be 
classified with reference to the pedicle of flap. According to this classification, there 
are two types of skin flaps, namely pedicled flaps and free flaps (Geiger et al., 2016). 
Pedicled flaps are created with its original blood supply intact, thus the donor site is 
usually not too distant from the recipient site. This type of flap does not require 
microsurgical anastomosis of the pedicle to re-establish the blood flow in the tissue 
transferred. As such, the time required for the procedure is shorter compared to free 
skin flaps, and the fact that the blood supply in the flap tissue remained intact 
throughout the surgical process ensure a high chance of flap survival. Hence, the 
pedicled flap is preferred in cases where the patient could not undergo long hours of 
surgery (McCrory and Magnuson, 2002). Nonetheless, there is limited options for 
pedicled flaps as its shape, mobility and position of the flap are greatly hampered by 
the pedicle. The possibility of pedicle entanglement during the transposition of the 
flap tissue also poses risk of causing inadequate blood supply in the flap, increasing 
the chances of flap necrosis and failure (O’Neill et al., 2010).  
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With the advancement of microsurgery and free tissue transfer, free flaps became a 
new option distinctive from the pedicled flap. Free flaps are created by total 
detachment from its donor site and transferred to the recipient site. Blood flow in the 
flap will then be re-established by surgical anastomosis of the arterial pedicle, and in 
some cases, anastomosis of the vein to increase venous output are also done. As it is 
not limited by the position of the pedicle, free flaps have a higher degree of freedom 
in terms of its location of harvest as well as position of the recipient site (Kruse et al., 
2010; Wu et al., 2014). However, the use of free skin flaps is also met by many 
challenges. Since the flap tissue is totally detached from the donor site, there will be 
a significant period of ischemia experienced by the flap tissue, causing unwanted 
stress and injury to the tissue structure. Thrombotic occlusion and the subsequent 
ischemic reperfusion injury after the flap is being anastomosed will also cause 
unwanted flap necrosis, as well as flap failure in severe cases (Kerrigan and Stotland, 
1993; Pattani et al., 2010; Siemionow and Arslan, 2004).  
 
1.2 Skin flap survival: Burden and challenges 
Recent advances in surgical equipment and technique oversaw marked improvements 
in skin flap success rates. Yet, complications of flap surgery, including partial and 
total skin flap failure remained a challenge for practitioners across the globe. 
Management of these complications are often expensive, and the morbidity and 
psychological stress that follows can be a burden to both patients and practitioners. 
Although there is lack of comprehensive review showing global or regional statistics 
of flap failure, there are abundant literature of individual report by practitioners and 
institutions documenting failure rates of flap transfer ranging from 5% to 10% 
(Phillips et al., 2012; Wang et al., 2012b; Wu et al., 2014).  
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In a paper published in 2011, it was reported that an estimated number of 19000 free 
tissue transfers were being performed in the United States alone in 2008 for a variety 
of reconstructive purposes. A total of 264 free flaps have been studied in a 
retrospective review in the Division of Plastic Surgery at Brigham and Women’s 
Hospital over a period of five years revealed that thrombosis related flap 
complications was about 4.9% with 1.9% total failures. The average cost disparity 
between flap complication and case-controlled uncomplicated flaps was about 
USD$ 23246 which is a burden especially in developing countries (Bowman and 
Carty, 2011). 
  
Another study conducted from January 2004 to April 2010 at Middlemore Hospital, 
New Zealand reported a success rate of 96% (Gao and Loo, 2011). However, a 
breakdown of the statistics reported shows that out of the 100 cases of free flap 
transfer, 21 cases presented with complications. Out of these, 14 cases were returned 
to the surgical table for salvage procedures. Among these, eight cases require a redo 
of the anastomoses. A total of four cases of total flap failure and five cases of partial 
flap failure were recorded.  
 
1.3 Pathophysiology of skin flap failure 
Ischemia of the flap tissue is the main culprit in most instances that lead up to flap 
failure. Ischemia is defined as a condition of inadequate blood supply to a certain 
area of tissue. Inadequate blood supply will lead to insufficient oxygen and nutrient 
intake by the cells in the area, forcing the tissue cells to adopt anaerobic metabolic 
pathways. Prolonged period of ischemia will lead to derangement of tissue health, 
8 
 
and will trigger a cascade of biochemical pathways that are detrimental to the 
survival of the tissue (Siemionow & Arslan, 2004). 
 
In the case of free skin flaps, the tissue lifted from the donor site experience a period 
of ischemia as soon as it is detached from the donor site. Depending on the surgical 
conditions, this period have an average range of about 1.5 hour to 3 hours. During 
this period, the flap is being transferred to the recipient site and vascular anastomosis 
is being performed. Although it may not be evident at this point, technical and 
physiologic factors occurring during this time could cause unwanted flap loss 
(Siemionow and Arslan, 2004).  
 
There is no definitive answer to how long the primary ischemic period will be 
tolerated, or when the injury from this period will become irreversible. The 
consensus is that increased ischemic period will lead to a decreased rate of flap 
survival, as well as a lower percentage of survival area. After the re-establishment of 
blood flow in the flap tissue, injury sustained during the ischemic period will most 
likely be reversed and the flap would survive. However, if an unwanted episode of 
secondary ischemia occurs, the injury induced will be even more lethal as a 
secondary ischemia is less tolerated by the tissue (Dorweiler et al., 2007).  
 
Flap loss is commonly categorised into partial and total flap failure. Partial flap loss 
is often associated with ischemia at the distal portion of the flap as a result of failure 
to maintain critical capillary pressure to perfuse the region. On the other hand, total 
flap failure is usually a consequence of secondary obstruction to the main supply 
vessel (pedicle), causing no-reflow phenomenon (Pang, 1990). Events of prolonged 
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ischemic period or occurrence of a secondary ischemia can be caused by a number of 
factors. These factors can be categorised into technical and physiological factors.  
 
1.3.1 Technical factors related to skin flap failure 
Technical factors are extrinsic factors that arise from problematic surgical procedures. 
While it may be unintentional, it could be reduced through experience and careful 
pre-operation planning by the surgeons.  
 
Anastomoses of the arterial inlet or venous output that are not properly done is a 
common cause of prolonged ischemia in flap surgery. Injury to the arterial inlet or a 
faulty suturing while reconnecting the pedicle would lead to blood loss at the pedicle. 
Loss of hemodynamic pressure at the pedicle of flap will greatly hamper the ability 
of the pedicle to properly supply the flap tissue, which would then lead to ischemia 
of the flap, especially at the region distant to the pedicle (Granzow et al., 2015).  
 
In some cases, especially among pedicled flaps, folding and entanglement of the 
pedicle causing inhibition of blood flow at the pedicle can also be a factor of 
prolonged ischemia. This can happen during the process of transposing the flap to the 
recipient site, where the flipping and rotational movement of the flap tissue resulting 
in the folding of the pedicle (Vaienti et al., 2013). 
 
The size of the flap is also a factor causing prolonged ischemia. As the flap tissue is 
being supplied by a sole pedicle, the decrease in hemodynamic pressure as blood 
travels farther away from the pedicle means that the farther the tissue from the 
pedicle, the harder it is to be perfused by the pedicle. As a result, the distal region 
10 
 
relative to the position of the pedicle, are at risk of prolonged ischemia, especially in 
oversized flaps (Shasti et al., 2017).  
 
1.3.2 Physiological factors related to skin flap failure 
Physiological factors of flap ischemia are intrinsic factors pertained to physiological 
changes that occur as a result of the flap surgery. These physiological factors include 
vasoconstriction of blood vessels in the flap tissue as well as occurrence of 
thrombosis in the flap. 
 
Vasoconstriction of the blood vessels, either at the pedicle or at the peripheral 
branches of arteriole, will inhibit blood flow towards an area of flap tissue. This will 
result in partial or total ischemia of in that area. As soon as the flap is being detached 
from the donor site, vasoconstriction occurs as a result of diminished blood flow. 
Vasoconstriction of the vessels may also induce other physiological changes such as 
release of thromboxane A2 and other toxic metabolites that will promote free radical 
induced damage to the tissue (Dorweiler et al., 2007).  
 
Thrombotic events during and after the flap surgery will lead to occlusion of blood 
vessels, causing prolonged ischemia. If the thrombotic event occurs after the re-
establishment of blood flow, a secondary ischemic insult will again cause more 
damage to the tissue. According to a study reported by Makiguchi and colleagues in 
2012, thrombotic events occurred at a rate of 7.5% in total of 200 cases of flap 
surgery in the head and neck region (Makiguchi et al., 2012). In a separate study by 
Bowman and Carty (2011), flap complications caused by thrombotic events were 
recorded at 4.9%. 
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1.4 Reperfusion injury 
Reperfusion injury is another aspect of concern in the pathophysiology of flap tissue 
failure. Although it is important to ensure that the flap is properly perfused after the 
surgery, the establishment of blood flow after the ischemic period will bring about 
physiological changes in the blood vessels that may eventually lead to additional 
tissue injury. This type of injury is termed ischemic reperfusion injury in free tissue 
transfer. While the susceptibility of a flap towards reperfusion injury differs in 
different type of flap tissue, it is well noted that the extent of reperfusion injury is 
proportionate to the length of ischemic period before reperfusion occurs (Wang et al., 
2011; Widgerow, 2014).  
 
During the reperfusion of flap tissue, inflammatory substrates that enters the tissue 
together with the restored blood flow, brings about free radical mediated damage to 
the tissue. These free radicals such as superoxide anion radical (O2
-
), hydrogen 
peroxide (H2O2), and the hydroxyl radical (OH), could cause structural changes to 
important biochemical molecules like amino acids, membrane surface proteins, 
cytochrome enzymes and nucleic acids (Dorweiler et al., 2007; Eisenhardt et al., 
2012; Manson et al., 1983; Siemionow and Arslan, 2004).  
 
1.5 Methods in improving skin flap survival 
Despite the high success rate of flap surgery, flap necrosis and failure still occur. 
This may result in a number of unwanted complications such as infections, loss of 
tissue function as well as cosmetic loss. Hence, many methods have been tried and 
studied over the decades to improve flap survival and to prevent post-operative 
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complications. These methods can be categorized into technical and pharmacologic 
interventions. 
 
1.5.1 Technical intervention in improving skin flap survival 
One of the common methods of improving the survival rate of flap tissue is by 
ischemic preconditioning, also known as a delayed flap. This is done by subjecting 
the donor tissue to short periods of ischemia prior to the surgery. The procedure is 
usually performed one to two weeks prior to the tissue transfer. In this way, the 
injury caused by the actual ischemic period during the flap surgery will be better 
tolerated by the flap tissue, resulting in higher rate of success (Ghali et al., 2007). 
 
Early effects of the delay procedure have been attributed to alteration of sympathetic 
tone, causing vasodilation by means of depleting norepinephrine in the sympathetic 
nerves. Other early effects include dilatation of choke vessels, as well as changes in 
tissue metabolism resulting in reduced metabolic requirements by tissue, less radical 
formations, and reduced infiltration of neutrophils and cell apoptosis allowing greater 
tolerance to ischemic insult (Maitz et al., 1994). Late effects of delay procedure 
oversee a series of anatomical changes in the flap tissue prior to the flap surgery. 
These changes include increase in vascular density by means of angiogenesis and 
vasculogenesis through the increased production and release of cytokines and 
angiogenic factors such as vascular endothelial growth factor (VEGF) (Holzbach et 
al., 2009). 
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Although the delay procedure is an effective technique in increasing the success rate 
of flap surgery, especially in reducing distal flap necrosis and partial flap failure, the 
technique requires a second surgical procedure and anesthesia which often leads to 
additional costs for both the healthcare system and patients (Ghali et al., 2007; 
Harder et al., 2008; Küntscher et al., 2005). 
 
1.5.2 Pharmacologic agents in improving flap survival 
Although surgical refinement has greatly increased the survival rate of skin flaps, 
skin flap failures were still being reported at about 2 - 10% of the cases, and 5 - 25% 
of free flaps require re-exploration due to compromised circulatory functions 
(Karsenti et al., 2010). Hence, in addition to improved surgical equipment, technique 
and procedural planning, plastic and reconstructive surgeons have experimented on 
various pharmacological agents to improve skin flap survival. These 
pharmacological agents often aimed to increase skin flap survival by improving 
blood perfusion in the transferred tissue or alleviating the effects of ischemic 
reperfusion injury.  
 
As tissue injury of skin flaps follows a complex series of pathophysiologic pathways, 
where processes such as thrombosis, ischemia reperfusion injury or the no-reﬂow 
phenomenon, and vasospasm may combine to play a role in causing skin flap failure. 
Hence, different pharmacological agents with different mechanisms may account for 
the improvement of skin flap survival, which may include prevention of 
microcirculatory failure, the inhibition of inflammation, and the induction of 
ischaemic tolerance (Harder et al., 2008). Thus, pharmacological treatments for 
complications in skin flap surgery may focus on thrombosis (anticoagulants), 
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ischemic reperfusion injury or no-reflow phenomenon (ischemic tolerance 
modulators such as antioxidants, free radical scavengers and growth factors), as well 
as vasospasm (vasodilators) (Hyza et al., 2014). 
 
Since the complication and failure of skin flap surgeries can manifest through a 
plethora of pathological processes, and in each case, a certain process predominates 
over the others, management of post-operative care in skin flap surgery depends 
greatly on the experience and individual preference of the surgeon in specific therapy 
selection (Hyza et al., 2014). Throughout the years, various pharmacologic agents 
have been proposed for improving skin flap survival, yet, there is no general 
consensus on treatment guidelines (Pršić et al., 2015). Although there were 
numerous animal studies on the different pharmacologic agents proposed along with 
few prospective clinical trials that dotted the literature, the lack of unified science 
behind the use of pharmacotherapy in the treatment of skin flaps resulted in 
anecdotal practice by individual surgeons with marked differences in medications, 
dosing and timing (Conrad and Adams, 2001). Owing to the extensive propositions 
of different pharmacologic agents in literature, many medications have been shown, 
to a certain extent, to be successful in improving skin flap survival. Thus, there are 
currently many pharmacologic agents that can be used in treating skin flaps, despite 
the absence of standard algorithm in their application. As such, drug choices may 
vary according to institutions, subjecting to the preferences of the practitioners as 
well as the availability of the individual medication (Ricci et al., 2016). A few of the 
commonly employed pharmacologic agents are further discussed in the entailing 
sections. 
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1.5.2 (a) Anti-thrombotic agents 
One of the major causes of flap failure is due to thrombosis of blood vessels in the 
flap tissue, resulting in inadequate blood flow. Hence, anti-coagulants and anti-
platelet medications have been used to prevent thrombosis in the flap post-
operatively. It is reported that about 96% of surgeons have used some form of 
antithrombotics post-operatively to improve flap survival (Glicksman et al., 1997; 
Spiegel and Polat, 2007). Anti-thrombotics used include Aspirin, low molecular 
weight dextran, heparin, prostaglandin E1 and tissue coagulative factor inhibitors. 
Although individual experiments have reported some degree of improvement in flap 
survival by applying antithrombotics post-operatively, broad scale reviews and meta-
analysis have shown little or no significant protective effect being conferred by anti-
coagulant therapy (Askari et al., 2006; Pršić et al., 2015). A systematic review with 
multicentre, individual patient data meta-analysis by Schwartz and colleagues in 
2015 have reported that antithrombotics did not significantly improve flap survival 
rate. They have also noted an increased in flap complications when heparin is 
administered in patients (Swartz et al., 2015).  
 
In another separate study, different antithrombotics were used on skin flaps in small 
animal models to elucidate the effects of these agents in improving the viability of 
skin flaps. However, the study shows that even though antithrombotics such as 
clopidogrel and hirudin improves the viability of skin flaps, these pharmacologic 
agents puts the subject at a higher risk of developing post-operative complications 
(Fichter et al., 2016). 
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1.5.2 (b) Vascular endothelial growth factor  
Growth factors, particularly vascular endothelial growth factor (VEGF), have the 
ability to induce vasodilation and angiogenesis. Thus, VEGF have long been 
suggested as a form of pharmacologic treatment to improve flap survival (Zhang et 
al., 2004).  
 
Vascular endothelial growth factor has been experimented on various animal models 
and have shown great promise in improving flap survival. Administration of VEGF 
can be done through intra-muscular, subcutaneous, subdermal, intra-arterial 
injections, systemic intake as well as topical applications. The treatment can be 
applied during the flap surgery (acute administration), or before the flap tissue is 
being raised for transfer (pre-operative treatment) (Kryger et al., 2000). 
 
The effects of VEGF include acute vasodilation and increased capillary permeation 
in flap tissue. It also stimulates migration and proliferation of endothelial cells, 
leading to formation of new microvessels. Formation of new microvessels eventually 
lead to increased vascular connections between the flap tissue and its underlying 
vascular bed (recipient site), promoting a variety of wound healing effects resulting 
in higher tissue survival rate (Fang et al., 2014; Michlits et al., 2007) 
  
Although various studies on VEGF treatment on flap surgery have shown promising 
results in increasing flap survival, the relatively short half-life of VEGF causes the 
availability of VEGF in the flap tissue to be poorly sustained (Taub et al., 1998). 
Attempts of increasing the availability of VEGF in situ by means of gene therapy 
have been experimented (Taub et al., 1998; Yu et al., 2003; Zheng et al., 2008). 
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However, these studies are limited to animal trials and its application remain 
prospective at best at the moment. Furthermore, despite improvements in skin flap 
survival were demonstrated in a number of studies using VEGF, the overall 
effectiveness of VEGF in treating flaps were not consistent (Fang et al., 2014). In 
some studies, the treated flaps shows survival rate as high as 97.2% (Yi et al., 2005), 
while in some studies, the survival rate of treated skin flaps was only 64.3% (Liu et 
al., 2005). 
 
1.5.2 (c) Free radical scavengers and antioxidants 
Release of reactive oxygen species such as superoxide, hydrogen peroxide, and 
hydroxyl, and the depletion of glutathione (an antioxidant) are responsible for 
causing cellular damage and tissue death in ischemic reperfusion injury (Dorweiler et 
al., 2007). A number of pharmacologic agents have been studied to address the 
detrimental effects of reactive oxygen species generated after the reperfusion of skin 
flap (Campos and Yoshida, 2004). These agents include free radical scavengers and 
antioxidants.   
 
Allopurinol is an inhibitor of xanthine oxidase, which reduces formation of reactive 
oxygen species. The effect of allopurinol on the survival of skin flaps have been 
studied for many years, yet the results remained controversial (Milcheski et al., 2013; 
Moura et al., 2009; Picard-Ami et al., 1992; Rees et al., 1994). A recent study 
reported in 2017 showed that systemic administration of allopurinol for one week 
prior to flap surgery showed protective effect on skin flaps (Ardakani et al., 2017). 
However, there is still no uniform and practical way of applying allopurinol in flap 
surgery and thus its practicality as a choice treatment remain inconclusive.  
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Another recent study by Fukunaga and colleagues studied the efficacy of a novel 
radical scavenger nitrosonifedipine in reducing ischemic necrosis of skin flap in 
mouse models. Daily dose of nitrosonifedipine (30 mg/kg) suspended in normal 
saline containing 1% carboxymethycellulose as vehicle was injected subcutaneously 
at the centre of the flap for up to a week. The study demonstrates that 
nitrosonifedipine reduces the percentage area of skin flap necrosis (approximately 20% 
increase in viable area),  and reduces cellular and tissue damage caused by oxidative 
stress (Fukunaga et al., 2017).  
Other antioxidants that have been tried to ameliorate skin flap survival includes 
vitamin C (ascorbic acid), melatonin, N-acetylcysteine, and superoxide dismutase. 
Although these agents have been shown to improve skin flap survival, neither of 
them has been tested and applied in standard clinical settings (Kerem et al., 2014; 
Tunç et al., 2016; Zaccaria et al., 1994). 
 
1.5.2 (d) Vasodilators 
Another major type of pharmacologic agents that have been identified as potential 
choice of treatment of skin flaps are vasodilators. Reducing the incidence of 
vasospasm and vasoconstriction after the flap surgery greatly reduces the ischemic 
period of skin flaps, especially at the distal part of the flap. In addition, it also 
reduces the chances of a secondary ischemia caused by vasoconstriction. 
Vasodilators can be broadly categorized into five types, namely, calcium channel 
blockers, local anaesthetics, alpha antagonists, direct vasodilators and 
phosphodiesterase inhibitors (Vargas et al., 2015).  
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Calcium channel blockers reduces intracellular calcium concentration in vascular 
smooth muscle cells by antagonising the voltage gated calcium channels. Decreased 
calcium concentration reduces rate of actin-myosin interaction, hence, relaxation of 
the vascular smooth muscle (Roland et al., 1998). Popular calcium channel blockers 
include nicardipine, verapamil and nifedipine. 
 
Local anaesthetics have spasmolytic effects on smooth muscles. Apart from that, it 
also prevents depolarisation and activation of calcium channel. These effects will 
allow the blood vessels to dilate, increasing blood flow into the flap tissue. Lidocaine 
is a type of local anaesthetic that have been widely tested for its effects in treating 
skin flaps (Hou et al., 1987). It has been shown that 12% lidocaine is effective in 
resolving microvascular constrictions on many occasions (Beekman et al., 1990; 
Beekman et al., 1988) , while in some other studies, 20% lidocaine have been 
reported to be effective (Johnstone et al., 1995; Puckett et al., 1985). However, these 
studies are limited to animal studies. Since the safety of lidocaine dosage in excess of 
2% have not been established for human use, the suitability of lidocaine for human 
flap surgery is very limited at this moment (Vargas et al., 2015). 
 
Activation of alpha adrenergic receptors stimulate release of calcium ions from the 
sarcoplasmic reticulum, which leads to contraction of vascular smooth muscles. 
Inhibition of these receptors allows the smooth muscles to relax, thus causing the 
blood vessels to dilate. Alpha adrenergic antagonists include phentolamine and 
chlorpromazine. Direct vasodilators such as sodium nitroprusside produces nitric 
oxide, which increases intracellular cyclic guanosine monophosphate, inhibition of 
myosin light chain kinase, and vasodilation. The efficacy of sodium nitroprusside as 
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a treatment for skin flap remain inconclusive as not all experimental results shown 
significant improvement after surgery. Furthermore, sodium nitroprusside produces 
harmful by-products such as methaemoglobin and cyanide in the body, increasing the 
metabolic burden on the patient (Huang and Li, 1991; Vargas et al., 2015; W. 
Notodihardjo et al., 1998).  
 
Phosphodiesterase inhibitors causes vasodilation by inhibiting phosphodiesterase and 
inactivates cyclic guanosine monophosphate. This leads to a secondary inhibitory 
effect on myosin light chain kinase, causing relaxation of smooth muscle cells in the 
blood vessels. A few phosphodiesterase inhibitors such as papaverine, pentoxifylline 
and amrinone have been studied and reviewed on its efficacy in reducing vasospasm 
in flap surgery. Papaverine and pentoxifylline have been shown to be effective in 
animal studies, though its usability in a human clinical setting have not been studied 
(Evans et al., 1997; Monteiro et al., 1986; Vargas et al., 2015). Amrinone, on the 
other hand, have been tried on human skin flap surgery. However, its adverse effects 
may hamper its application in clinical use (Ichioka et al., 2001).  
 
In recent years, a specific type of phosphodiesterase inhibitors, namely 
phosphodiesterase type 5 (PDE-5) inhibitors, have been the target of many studies on 
its effect on improving skin flap survival (Bandera et al., 2010; Brewer et al., 2012; 
Kayiran et al., 2013). The notable examples of PDE-5 inhibitors are sildenafil, 
vardenafil and tadalafil. This type of drugs prevents the degradation of 3’,5’-
guanosine monophosphate (cGMP), which are responsible for vasodilation and 
relaxation of cavernosal smooth muscles. Currently, PDE-5 inhibitors are mainly 
indicated for the treatment of erectile dysfunction (Gresser and Gleiter, 2002; 
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Jackson et al., 2005) and treatment of pulmonary hypertension in infants (Iacovidou 
et al., 2012; Wang et al., 2014). In a study reported by Kaya and colleagues in 2015, 
oral administration of sildenafil, vardenafil and tadalafil significantly improves the 
survival rate of skin flaps in rats (Kaya et al., 2015). 
 
1.6 Sildenafil as a potential treatment to improve skin flap survival rate 
1.6.1 Brief history of sildenafil 
Sildenafil is a type of PDE-5 inhibitor discovered by scientists in Pfizer’s European 
Research HQ in Sandwich, UK. Figure 1.1 shows the chemical structure of sildenafil 
citrate. It was originally developed to treat angina by augmenting the nitric oxide 
mediated cyclic guanosine monophosphate synthesis pathway (cGMP) (Jackson et 
al., 2005). Cyclic guanosine monophosphate causes arteries to dilate by initiating the 
relaxation of vascular smooth muscles, thus increasing blood flow in the arteries. 
Sildenafil does not directly increase nitric oxide levels like other commonly used 
nitrate drugs during the 1980s and 1990s. Rather, it inhibits the PDE-5 mediated 
hydrolysis of cGMP, resulting in increased cGMP levels. Hence, it was hypothesised 
that sildenafil can be used as a vasodilator without the adverse effects of nitric oxide 
(Connelly, 2017). Figure 1.2 shows a schematic diagram of how PDE-5 inhibitors 
such as sildenafil can augment the vasodilatory effect of the nitric oxide/cGMP 
pathway. 
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Figure 1.1  Chemical structure of sildenafil citrate. Source: PubChem, Compound 
Summary for CID 62853. Image retrieved on June 2
nd
, 2018. Image 
source: 
https://pubchem.ncbi.nlm.nih.gov/compound/Sildenafil_citrate#sectio
n=Top  
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Figure 1.2  Molecular events in a soluble guanylyl cyclase signaling pathway. The 
soluble guanylyl cyclase can be activated pharmacologically and 
physiologically by the gaseous messengers (indicated by the (+) sign). 
Inhibitors of the cGMP PDE will amplify (+) responses downstream 
(e.g., on CNG channels, kinases) and, depending on the simultaneous 
presence of PDE-3, even amplify cAMP signaling.  
 
Image source: Glossmann, H., Petrischor, G., & Bartsch, G. (1999). Molecular 
mechanisms of the effects of sildenafil (VIAGRA®). Experimental 
gerontology, 34(3), 305-318. 
 
Abbreviations: 
NO  : Nitric oxide 
CO : Carbon monoxide 
cGMP : Cyclic guanosine monophosphate 
CNG : Cyclic nucleotide-gated channels 
PDE : Phosphodiesterase 
cAMP : Cyclic adenosine monophosphate 
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Its relatively short half-life of four hours, and the fact that its haemodynamic 
properties have not been shown to be significantly superior over the nitrate drugs, 
there was limited usage of sildenafil to treat angina (Nichols et al., 2002). Despite 
that, it was noticed that among the few of the noted side effects of sildenafil such as 
flushing, headache, dizziness, nasal congestion, heartburn, dyspepsia and visual 
disturbance (Dündar et al., 2001; Moreira Jr et al., 2000; Vobig et al., 1999), penile 
erection stood out among them. At the time, there is no oral medication for the 
treatment of erectile dysfunction. Thus, the idea of utilizing sildenafil as a potential 
oral medication for erectile dysfunction (ED) prompted the scientists at Pfizer to 
switch focus and by March 27, 1998, the FDA of the United States of America 
approved the use of sildenafil as an oral treatment for erectile dysfunction  (Jackson 
et al., 2005).  
 
Although sildenafil is currently only approved for the treatment of ED, ongoing 
investigations are being carried out to study its potential application in other clinical 
areas. These include studies on its potential in treating premature ejaculation 
(McMahon et al., 2003; Salonia et al., 2002), female sexual dysfunction (Laan et al., 
2002), as well as cardiovascular diseases (Lundberg et al., 2015; Wang et al., 2012a). 
The results of these studies are mixed and many of them are still in preclinical or 
early clinical studies (Jackson et al., 2005).  
 
1.6.2 Effect of Sildenafil on Skin Flap Survival 
Vasodilators have been implicated to be useful in treating skin flaps to reduce 
necrosis area and to improve skin flap viability. Among the numerous vasodilators 
reported to have a beneficial effect on skin flap survival, sildenafil appears to be a 
